Gelonghui, April 30丨Yuandong Biology (688513.SH) announced that the phase III clinical trial of the self-developed Class 1 new drug eugliptin tablets to treat type 2 diabetes as a single agent has recently obtained a clinical trial summary report and achieved the expected goals. Phase III clinical trial results showed that euglithin tablets can significantly improve glycated hemoglobin (HbA1c), fasting blood sugar, and blood sugar 2 hours after meals in patients with type 2 diabetes who have poor exercise control on a simple diet. Euglitine tablets as a single drug can significantly improve the patient's glycated hemoglobin, fasting blood sugar, and blood sugar 2 hours after meals in Chinese patients with poor exercise control on a simple diet, and the effect lasts for a long time. Euglitine tablets are safe and well tolerated for long-term use, and the test results achieved the expected goals.
苑东生物(688513.SH)：优格列汀片单药治疗2型糖尿病III期临床试验达到预期目标
Yuandong Biotech (688513.SH): Phase III clinical trial of eugliptin tablets as a single agent to treat type 2 diabetes reached the expected goals
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.